EU approves new antibiotic to tackle rise of superbugs

  25 April 2024

The European Commission has approved a new antibiotic, Emblaveo, for serious illnesses like pneumonia and urinary tract infections. Emblaveo, marketed by US pharmaceutical company Pfizer, combines two existing medicines to tackle Gram-negative bacteria, which are among the leading drug-resistance threats. The treatment is likely to be used in a narrow group of serious cases to reduce the risk of triggering a surge in anti-microbial resistance (AMR). The European Commission is the first authority to approve the treatment, and health policymakers are trying to provide an incentive to pharma businesses to invest more in dealing with pathogen resistance. AMR is estimated to be linked to 5 million deaths a year worldwide. Emblaveo is the second antibiotic the EU has approved this year, after Exblifep. It will be marketed against bacteria that produce enzymes known as Metallo β-lactamases (MBL), which break the structure of many existing antibiotics, destroying their efficacy.

Further reading: Financial Times
Author(s): Ian Johnston and Michael Peel
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed